CIK 0001593899 · Non-accelerated filer<br>Smaller reporting company
Atea Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AVIR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 460574869
- Phone
- (857) 284-8891
- Business address
- 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-31 | Sommadossi Jean-Pierre President, CEO, and Chairman | Grant or award · Stock Option (Right to Buy) | +728,600 | 728,600 | ||
| 2023-01-31 | Corcoran Andrea See Remarks | Grant or award · Restricted Stock Units | +133,100 | 133,100 | ||
| 2023-01-31 | Corcoran Andrea See Remarks | Grant or award · Stock Option (Right to Buy) | +186,300 | 186,300 | ||
| 2023-01-31 | Hammond Janet MJ Chief Development Officer | Grant or award · Restricted Stock Units | +140,400 | 140,400 | ||
| 2023-01-31 | Hammond Janet MJ Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +196,600 | 196,600 | ||
| 2023-01-31 | Vavricka John Chief Commercial Officer | Grant or award · Restricted Stock Units | +100,000 | 100,000 | ||
| 2023-01-31 | Vavricka John Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2022-11-14 | BERGER FRANKLIN M Director | Sale | −16,166 | $5.16 | $83K | 778,353 |
| 2022-11-11 | BERGER FRANKLIN M Director | Sale | −25,500 | $5.15 | $131K | 794,519 |
| 2022-06-17 | Duncan Barbara Gayle Director | Grant or award · Stock Option (Right to Buy) | +61,264 | 61,264 | ||
| 2022-06-17 | BERGER FRANKLIN M Director | Grant or award · Stock Option (Right to Buy) | +61,264 | 61,264 | ||
| 2022-06-17 | Adams Jerome M. Director | Grant or award · Stock Option (Right to Buy) | +61,264 | 61,264 | ||
| 2022-06-17 | Murphy Polly A. Director | Grant or award · Stock Option (Right to Buy) | +61,264 | 61,264 | ||
| 2022-06-17 | Lucidi Bruno Director | Grant or award · Stock Option (Right to Buy) | +61,264 | 61,264 | ||
| 2022-06-17 | Polsky Bruce Director | Grant or award · Stock Option (Right to Buy) | +61,264 | 61,264 | ||
| 2022-01-31 | Vavricka John Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2022-01-31 | Horga Maria Arantxa Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +170,000 | 170,000 | ||
| 2022-01-31 | Corcoran Andrea See Remarks | Grant or award · Stock Option (Right to Buy) | +181,000 | 181,000 | ||
| 2022-01-31 | Foster Wayne EVP, Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2022-01-31 | Sommadossi Jean-Pierre President, CEO, and Chairman | Grant or award · Stock Option (Right to Buy) | +378,033 | 378,033 |
Page 11 of 14 · 280 trades